"With granted patents, we are on track to secure a patent family that can lead to new screening methods for diagnosing cancer at an early stage. The grants in the US and
PHI submitted the granted patent application "Molecularly Imprinted Polymers" (JP2017559614) together with
Synthetic antibodies
The granted patents protects technology for creating synthetic plastic antibodies that can be tailored to recognize and bind to specific molecules with high precision to, for example, identify cancer cells in blood or tissue samples.
The synthetic antibodies are developed within the joint project GlycoImaging where PHI participated with Malmö University and four other research institutes. PHI holds the commercial rights to the innovation, owning 75 % of the patents, while BAM owns the remaining 25 %.
For additional information, please contact:
E-mail: ir@phiab.se
Web: www.phiab.com - Live cell imaging & analysis
https://news.cision.com/phase-holographic/r/synthetic-antibody-patent-awarded-to-phi-by-japan,c3584052
https://mb.cision.com/Main/11597/3584052/1591828.pdf
https://news.cision.com/phase-holographic/i/molecularly-imprinted-polymers-mip,c3059942
(c) 2022 Cision. All rights reserved., source